N-acetyl cysteine induces quiescent-like pancreatic stellate cells from an active state and attenuates cancer-stroma interactions.
Cancer-stromal interactions
N-acetyl-cysteine
Pancreatic Cancer
Pancreatic stellate cells
Pioglitazone
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
15 Apr 2021
15 Apr 2021
Historique:
received:
06
10
2020
accepted:
06
04
2021
entrez:
16
4
2021
pubmed:
17
4
2021
medline:
20
11
2021
Statut:
epublish
Résumé
Pancreatic stellate cells (PSCs) occupy the majority of the pancreatic cancer microenvironment, contributing to aggressive behavior of pancreatic cancer cells (PCCs). Recently, anti-fibrotic agents have proven to be an effective strategy against cancer, but clinical trials have shown little efficacy, and the driving mechanism remains unknown. N-acetyl-cysteine (NAC) is often used for pulmonary cystic fibrosis. Pioglitazone, an agonist of peroxisome proliferator-activated receptor gamma, was habitually used for type II diabetes, but recently reported to inhibit metastasis of PCCs. However, few studies have focused on the effects of these two agents on cancer-stromal interactions. We evaluated the expression of α-smooth muscle actin (α-SMA) and the number of lipid droplets in PSCs cultured with or without NAC. We also evaluated changes in invasiveness, viability, and oxidative level in PSCs and PCCs after NAC treatment. Using an indirect co-culture system, we investigated changes in viability, invasiveness, and migration of PSCs and PCCs. Combined treatment effects of NAC and Pioglitazone were evaluated in PSCs and PCCs. In vivo, we co-transplanted KPC-derived organoids and PSCs to evaluate the effects of NAC and Pioglitazone's combination therapy on subcutaneous tumor formation and splenic xenografted mouse models. In vitro, NAC inhibited the viability, invasiveness, and migration of PSCs at a low concentration, but not those of PCCs. NAC treatment significantly reduced oxidative stress level and expression of α-SMA, collagen type I in PSCs, which apparently present a quiescent-like state with a high number of lipid droplets. Co-cultured PSCs and PCCs mutually promoted the viability, invasiveness, and migration of each other. However, these promotion effects were attenuated by NAC treatment. Pioglitazone maintained the NAC-induced quiescent-like state of PSCs, which were reactivated by PCC-supernatant, and enhanced chemosensitivity of PCCs. In vivo, NAC and Pioglitazone's combination suppressed tumor growth and liver metastasis with fewer stromal components and oxidative stress level. NAC suppressed activated PSCs and attenuated cancer-stromal interactions. NAC induces quiescent-like PSCs that were maintained in this state by pioglitazone treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Pancreatic stellate cells (PSCs) occupy the majority of the pancreatic cancer microenvironment, contributing to aggressive behavior of pancreatic cancer cells (PCCs). Recently, anti-fibrotic agents have proven to be an effective strategy against cancer, but clinical trials have shown little efficacy, and the driving mechanism remains unknown. N-acetyl-cysteine (NAC) is often used for pulmonary cystic fibrosis. Pioglitazone, an agonist of peroxisome proliferator-activated receptor gamma, was habitually used for type II diabetes, but recently reported to inhibit metastasis of PCCs. However, few studies have focused on the effects of these two agents on cancer-stromal interactions.
METHOD
METHODS
We evaluated the expression of α-smooth muscle actin (α-SMA) and the number of lipid droplets in PSCs cultured with or without NAC. We also evaluated changes in invasiveness, viability, and oxidative level in PSCs and PCCs after NAC treatment. Using an indirect co-culture system, we investigated changes in viability, invasiveness, and migration of PSCs and PCCs. Combined treatment effects of NAC and Pioglitazone were evaluated in PSCs and PCCs. In vivo, we co-transplanted KPC-derived organoids and PSCs to evaluate the effects of NAC and Pioglitazone's combination therapy on subcutaneous tumor formation and splenic xenografted mouse models.
RESULTS
RESULTS
In vitro, NAC inhibited the viability, invasiveness, and migration of PSCs at a low concentration, but not those of PCCs. NAC treatment significantly reduced oxidative stress level and expression of α-SMA, collagen type I in PSCs, which apparently present a quiescent-like state with a high number of lipid droplets. Co-cultured PSCs and PCCs mutually promoted the viability, invasiveness, and migration of each other. However, these promotion effects were attenuated by NAC treatment. Pioglitazone maintained the NAC-induced quiescent-like state of PSCs, which were reactivated by PCC-supernatant, and enhanced chemosensitivity of PCCs. In vivo, NAC and Pioglitazone's combination suppressed tumor growth and liver metastasis with fewer stromal components and oxidative stress level.
CONCLUSION
CONCLUSIONS
NAC suppressed activated PSCs and attenuated cancer-stromal interactions. NAC induces quiescent-like PSCs that were maintained in this state by pioglitazone treatment.
Identifiants
pubmed: 33858491
doi: 10.1186/s13046-021-01939-1
pii: 10.1186/s13046-021-01939-1
pmc: PMC8050903
doi:
Substances chimiques
Acetylcysteine
WYQ7N0BPYC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
133Références
J Hazard Mater. 2019 Nov 5;379:120794
pubmed: 31238218
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Br J Cancer. 2012 Sep 25;107(7):1153-8
pubmed: 22929879
Oncol Lett. 2014 Dec;8(6):2709-2714
pubmed: 25364454
Cell. 2005 Dec 16;123(6):993-9
pubmed: 16360030
Gastroenterology. 1998 Aug;115(2):421-32
pubmed: 9679048
World J Gastroenterol. 2017 Jan 21;23(3):382-405
pubmed: 28210075
Cell Mol Life Sci. 2003 Jan;60(1):6-20
pubmed: 12613655
Gastroenterology. 2005 Apr;128(4):907-21
pubmed: 15825074
Cancer Res. 2013 Apr 1;73(7):2345-56
pubmed: 23348422
Gut. 2011 Jun;60(6):861-8
pubmed: 20966025
Cancer Sci. 2016 Oct;107(10):1443-1452
pubmed: 27487486
Dig Dis Sci. 2016 Jun;61(6):1561-71
pubmed: 26738736
Mol Cancer. 2013 Aug 02;12:86
pubmed: 23915189
Mol Cancer. 2018 Feb 19;17(1):62
pubmed: 29458370
J Exp Clin Cancer Res. 2019 May 27;38(1):221
pubmed: 31133044
Cancer Cell. 2014 Jun 16;25(6):719-34
pubmed: 24856586
Cancer Res. 2004 May 1;64(9):3215-22
pubmed: 15126362
Lancet. 2016 Jul 2;388(10039):73-85
pubmed: 26830752
N Engl J Med. 2005 Nov 24;353(21):2229-42
pubmed: 16306520
Science. 2009 Jun 12;324(5933):1457-61
pubmed: 19460966
Cancer Cell. 2010 Feb 17;17(2):135-47
pubmed: 20138012
Cancer Cell. 2014 Jun 16;25(6):735-47
pubmed: 24856585
Diabetes Ther. 2017 Aug;8(4):705-726
pubmed: 28623552
Am J Pathol. 2010 Nov;177(5):2585-96
pubmed: 20934972
J Biol Chem. 2004 Nov 26;279(48):50455-64
pubmed: 15375156
Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4318-23
pubmed: 9113987
Cancer Discov. 2016 Aug;6(8):852-69
pubmed: 27246539
JCI Insight. 2017 Feb 9;2(3):e88032
pubmed: 28194432
Neoplasia. 2013 Apr;15(4):409-20
pubmed: 23555186
Curr Opin Cell Biol. 2015 Oct;36:13-22
pubmed: 26183445
Biochem Pharmacol. 2004 Mar 15;67(6):1215-25
pubmed: 15006556
Oncotarget. 2016 Jul 5;7(27):41825-41842
pubmed: 27259232
Cancer Res. 2013 May 15;73(10):3007-18
pubmed: 23514705
World J Gastroenterol. 2014 Mar 7;20(9):2237-46
pubmed: 24605023
J Cell Mol Med. 2011 Mar;15(3):635-46
pubmed: 20184663
Gastroenterology. 2010 Sep;139(3):1041-51, 1051.e1-8
pubmed: 20685603
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Hepatobiliary Surg Nutr. 2016 Feb;5(1):1-14
pubmed: 26904552
Gastroenterology. 2017 May;152(6):1492-1506.e24
pubmed: 28126348
Cancer Lett. 2018 Jul 1;425:65-77
pubmed: 29580808
Gut. 1999 Apr;44(4):534-41
pubmed: 10075961
Adv Pharmacol. 1997;38:205-27
pubmed: 8895810
Eur Respir J. 2004 Apr;23(4):629-36
pubmed: 15083766
Gastroenterology. 2000 Aug;119(2):466-78
pubmed: 10930382